GLP-1 receptor agonists in pediatric obesity.

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver

GLP-1 Receptor Agonist Therapy in Children and Adolescents with Obesity: A Network Meta-Analysis of Differential Cardiometabolic Efficacy and Safety Profiles.

Pharmacological research

Time to benefit of incretin-based therapies in adiposity-related heart failure with mildly reduced or preserved ejection fraction: a systematic review and meta-analysis.

Journal of cardiac failure

GLP-1 receptor agonists in ADPKD: from metabolic rationale to phenotype-enriched translational testing.

Translational research : the journal of laboratory and clinical medicine

GLP-1 Agonists and Risk of Atrial Fibrillation in Non-Dialysis Chronic Kidney Disease.

Cardiovascular drugs and therapy

Resmetirom and semaglutide therapy for patients with MAFLD in the MENA region: expert panel recommendations.

Expert review of endocrinology & metabolism

Effect of Semaglutide on Measured vs Estimated Glomerular Filtration Rate.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

Concurrent diabetic ketoacidosis, acute pancreatitis, and subsequent ruptured acalculous cholecystitis in a patient receiving semaglutide: A case report.

SAGE open medical case reports

💉Peptides with known receptors: Semaglutide Tirzepatide Retatrutide CJC-1295 Sermorelin Tesamorelin Ipamorelin GHRP-2 GHRP-6 Hexarelin Oxytocin Kisspeptin-10 PT-141 / Bremelanotide Melanotan II Humanin Insulin Growth hormone Peptides without receptors: BPC-157 TB-500

BREAKING $HIMS Another Upgrade| $40| BUY rating🚀 This only proves @MikeLongTerm was right again and again and again! These PTs are still very behind with FY2026 Revenue and earning growth or FY2027. Analysts will soon be revised nonstop to 3 digits IMO. Not Financial Advice! https://t.co/P53V80HOpX https://t.co/6xXvbCMgBK

https://t.co/XHq5rZw8Em The article reports that the FDA has significantly changed the makeup of the upcoming advisory panel that will review several peptide drugs, including BPC-157 and TB-500, ahead of the July meeting. New panel composition: Previous FDA advisory panels were

Same molecule, different name. The GLP-1 maze decoded: Ozempic = semaglutide (diabetes) Wegovy = semaglutide (weight) Rybelsus = semaglutide (pill) Mounjaro = tirzepatide (diabetes) Zepbound = tirzepatide (weight) Victoza = liraglutide (diabetes) Saxenda = liraglutide (weight)

Top compounds on PeptideBase by provider coverage: 1. Semaglutide — 676 2. Tirzepatide — 444 3. BPC-157 — 402 4. NAD+ — 349 5. Sermorelin — 333 6. Ipamorelin — 320 7. CJC-1295 — 306 Coverage = where the market concentrated, not where the evidence is. Disclaimer: Research use

Semaglutide is on 676 of the providers we list, the widest network of any compound. Then it drops: Tirzepatide: 444 BPC-157: 402 NAD+: 349 Sermorelin: 333 Availability tracks demand, not evidence. Disclaimer: We're a research first platform, we don't sell, recommend, or

FDA-approved, by brand name: Semaglutide → Ozempic, Wegovy Tirzepatide → Mounjaro, Zepbound Tesamorelin → Egrifta Most of the rest of the typical "peptide stack"? Not approved. Research status ≠ approval status.

I've stayed quiet about this for quite some time while I've been building — but many of you might remember that I was a certified FDN functional medicine practitioner for many years. And some of you might be curious about peptides, which seem to be all the craze lately. You